| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.04 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.065 | 0.05 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.091 | 0.05 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.064 | 0.05 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |